- Home
- NRK vs GHRS Comparison
NRK vs GHRS Comparison
Compare NRK & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRK
- GHRS
- Stock Information
- Founded
- NRK 2002
- GHRS 2018
- Country
- NRK United States
- GHRS Ireland
- Employees
- NRK N/A
- GHRS N/A
- Industry
- NRK Trusts Except Educational Religious and Charitable
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- NRK Finance
- GHRS Health Care
- Exchange
- NRK Nasdaq
- GHRS Nasdaq
- Market Cap
- NRK 922.1M
- GHRS 849.8M
- IPO Year
- NRK N/A
- GHRS 2021
- Fundamental
- Price
- NRK $9.76
- GHRS $12.31
- Analyst Decision
- NRK
- GHRS Strong Buy
- Analyst Count
- NRK 0
- GHRS 8
- Target Price
- NRK N/A
- GHRS $30.63
- AVG Volume (30 Days)
- NRK 187.3K
- GHRS 193.5K
- Earning Date
- NRK 01-01-0001
- GHRS 05-08-2025
- Dividend Yield
- NRK 4.10%
- GHRS N/A
- EPS Growth
- NRK N/A
- GHRS N/A
- EPS
- NRK N/A
- GHRS N/A
- Revenue
- NRK N/A
- GHRS N/A
- Revenue This Year
- NRK N/A
- GHRS N/A
- Revenue Next Year
- NRK N/A
- GHRS N/A
- P/E Ratio
- NRK N/A
- GHRS N/A
- Revenue Growth
- NRK N/A
- GHRS N/A
- 52 Week Low
- NRK $8.95
- GHRS $6.00
- 52 Week High
- NRK $11.09
- GHRS $20.50
- Technical
- Relative Strength Index (RSI)
- NRK 43.10
- GHRS 52.37
- Support Level
- NRK $9.72
- GHRS $12.43
- Resistance Level
- NRK $9.84
- GHRS $13.15
- Average True Range (ATR)
- NRK 0.06
- GHRS 0.99
- MACD
- NRK 0.01
- GHRS -0.14
- Stochastic Oscillator
- NRK 38.57
- GHRS 41.03
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.